Dakota Wealth Management Has $2.98 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dakota Wealth Management decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 78.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,408 shares of the pharmaceutical company’s stock after selling 26,985 shares during the period. Dakota Wealth Management’s holdings in Vertex Pharmaceuticals were worth $2,983,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in VRTX. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $27,000. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth $35,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ VRTX opened at $428.00 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The business has a 50-day simple moving average of $438.10 and a two-hundred day simple moving average of $465.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the previous year, the company earned $3.67 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Scotiabank increased their price objective on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a “sector perform” rating in a research note on Monday, December 23rd. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Finally, BMO Capital Markets decreased their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.